A patent application has been filed for a new cannabinoid-based topical therapy that will treat glaucoma, the second-leading cause of blindness.
Vancouver-based InMed Pharmaceuticals, a pre-clinical stage biopharmaceutical company that specializes in the pharmacology of cannabinoids, has filed a provisional patent application in the United States for INM-085.
With a global market share of $5 billion, the group of eye diseases known as glaucoma affect a significant number of individuals throughout the world. Risk factors for the disease include increased pressure in the eye, family history, high blood pressure, migraines and even obesity.
In the past, investigators have determined that complex dosage schedules have contributed to poor adherence from patients, ultimately leading to less than ideal treatment outcomes. Patient adherence would likely improve with the once a day, before bed routine offered by INM-085.
The topical therapy is used as an eye drop by patients each night before bed and works to relieve the intraocular pressure associated with glaucoma. The stimulus-responsive, nanoparticle-laden vehicle being developed by InMed for delivery into the aqueous humor of the eye may present other opportunities as well and the company has plans to initiate discussion with potential partners to that end.
Alerts Sign-up